Conditions: Asthma
Keywords: Asthma Interleukin QBX258 QAX576 VAK694
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 65
Healthy volunteers: no

Brief summary:
This study is designed to investigate the efficacy and safety of QBX258 in subjects with moderate to severe asthma.

Detailed description:

Arms:
arm 1: Participants received QBX258 intravenous (iv) infusion every 4 weeks for up to 4 doses total. arm 2: Participants received placebo to QBX258 iv infusion every 4 weeks for up to 4 doses total.

Interventions: intervention 1: QBX258 intervention 2: Placebo
Intervention descriptions: intervention 1: QBX258 infusion, a combination of VAK694 and QAX576, was supplied to the Investigator as open label bulk medication. The planned dose of VAK694 (lyophilisate in vial, 150 mg/vial), was 3 mg/kg. The planned dose of QAX576 (lyophilisate in vial, 150 mg/vial), was 6 mg/kg. intervention 2: The placebo infusion was an equal volume of 5% dextrose for infusion and was provided by the clinical site.

Protocol document: